Participated as existing investor in Ray Therapeutics' upsized and oversubscribed $125M Series B for optogenetic retinal disease therapies.
Ray Therapeutics is a clinical-stage biotechnology company developing best-in-class vision restoration therapies for people with degenerative retinal diseases independent of genetic mutation, utilizing optogenetics technology
Ray Therapeutics is a clinical-stage biotechnology company developing best-in-class vision restoration therapies for people with degenerative retinal diseases independent of genetic mutation, utilizing optogenetics technology.